Financial Comparison: Erasca (NASDAQ:ERAS) vs. Oncolytics Biotech (NASDAQ:ONCY)

Oncolytics Biotech (NASDAQ:ONCY) and Erasca (NASDAQ:ERAS) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, institutional ownership and profitability.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Oncolytics Biotech and Erasca, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncolytics Biotech	1	1	2	1	2.60
Erasca	2	1	7	0	2.50

Oncolytics Biotech presently has a consensus target price of $8.50, indicating a potential upside of 679.82%. Erasca has a consensus target price of $16.63, indicating a potential downside of 26.01%. Given Oncolytics Biotech’s stronger consensus rating and higher probable upside, equities analysts plainly believe Oncolytics Biotech is more favorable than Erasca.

Earnings & Valuation

This table compares Oncolytics Biotech and Erasca”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncolytics Biotech	N/A	N/A	-$28.76 million	($0.29)	-3.76
Erasca	N/A	N/A	-$124.55 million	($0.44)	-51.07

Erasca is trading at a lower price-to-earnings ratio than Oncolytics Biotech, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Oncolytics Biotech has a beta of 0.98, indicating that its stock price is 2% less volatile than the S&P 500. Comparatively, Erasca has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500.

Institutional and Insider Ownership

6.8% of Oncolytics Biotech shares are held by institutional investors. Comparatively, 67.8% of Erasca shares are held by institutional investors. 0.1% of Oncolytics Biotech shares are held by insiders. Comparatively, 14.4% of Erasca shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Oncolytics Biotech and Erasca’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Oncolytics Biotech	N/A	-2,185.97%	-243.94%
Erasca	N/A	-34.48%	-28.74%

About Oncolytics Biotech

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

About Erasca

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company’s lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.